What is Lucid Diagnostics's R&D?

Lucid Diagnostics (LUCD) reported R&D of $1.21M in Q1 2026.

How has Lucid Diagnostics's R&D changed year-over-year?

Lucid Diagnostics's R&D decreased by 15.5% year-over-year, from $1.43M to $1.21M.

What is the long-term trend for Lucid Diagnostics's R&D?

Over 4 years (2021 to 2025), Lucid Diagnostics's R&D has grown at a -11.6% compound annual growth rate (CAGR), from $9.3M to $5.68M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Lucid Diagnostics LUCD R&D

R&D at other companies

Castle BiosciencesCSTL

$14.43M+14.6%

Guardant HealthGH

$91.04M+2.8%

Biodesix, Inc.BDSX

$3.29M+14.5%

Insight Molecular Diagnostics Inc. Common StockIMDX

$4.95M+69.4%

Fulgent Genetics, Inc.FLGT

$14.18M+14.4%

Personalis, Inc.PSNL

$14.54M+15.0%

Other financials

Income statement

See full

Revenue$1.3M+51.7%

Gross profit-$369.0K+49.0%

Operating income-$12.1M+3.0%

Net income-$13.9M+48.3%

EPS (diluted)-$0.10+60.0%

Balance sheet

See full

Cash & equivalents$27.9M+10.6%

Total debt$1.6M-35.1%

Total equity$4.0M+174%

Total assets$34.1M+3.9%

Cash flow

See full

Operating cash flow-$12.1M+2.9%

CapEx$215.0K+131%

Free cash flow-$12.3M+1.9%

Valuation

See full

Market cap$204.13M+58.5%

Enterprise value$177.85M+78.0%

P/S39.8×+10.2×

Profitability

See full

Gross margin-66.8%—

Operating margin-959.6%-133pp

Net margin-876.7%-254pp

FCF margin-1,099.6%—

Returns & leverage

See full

Return on equity-710.6%—

Debt / equity0.4×—

Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lucid Diagnostics's R&D?: Lucid Diagnostics (LUCD) reported R&D of $1.21M in Q1 2026.
How has Lucid Diagnostics's R&D changed year-over-year?: Lucid Diagnostics's R&D decreased by 15.5% year-over-year, from $1.43M to $1.21M.
What is the long-term trend for Lucid Diagnostics's R&D?: Over 4 years (2021 to 2025), Lucid Diagnostics's R&D has grown at a -11.6% compound annual growth rate (CAGR), from $9.3M to $5.68M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.